Ben Samelson-Jones: Long-Term Safety and Efficacy of AAV Gene Therapy Using FIX-Padua in Hemophilia B
Ben Samelson-Jones, Associate Director of Clinical In Vivo Gene Therapy at Children’s Hospital of Philadelphia and Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Sustained long term safety and efficacy (up to 6 years) with AAV gene therapy using FIX-Padua for hemophilia B.”
Title: Safety, efficacy and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B
Authors: Benjamin J Samelson-Jones, John EJ Rasko, Jonathan Ducore, Catherine McGuinn, Lindsey A. George, Sylvia von Mackensen, Gianluca Borgonuovo, Delphine Agathon, Lynne Smith, Lisa J Wilcox, Francesca Biondo, Frank Plonski
Read the Full Article on Blood Advances
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 18, 2026, 12:22Anita Brikman: Advancing Plasma-Derived Therapies in India Through Global Collaboration
-
Mar 18, 2026, 12:14Sakditad Saowapa: Optimizing Sexual Activity and Minimizing Infection Risk in Patients with Neutropenia
-
Mar 17, 2026, 18:11Ossama Mansour: Landmark MENA Guidelines for Acute Ischemic Stroke Management
-
Mar 17, 2026, 17:48Andrea Van Beek: Improving DOAC Adherence Saves Lives
-
Mar 17, 2026, 17:43Soumen Bhattacharyya: Microangiopathic Hemolytic Anemia Is Often a Hematologic Clue to Underlying Malignancy
-
Mar 17, 2026, 17:37Peter Bou Dib: New Insights on Factor VIII and the Musculoskeletal System
-
Mar 17, 2026, 17:31Armghan Ans: The 2026 Stroke Guidelines Are Excellent, Now the Hard Part
-
Mar 17, 2026, 17:26Danny Hsu: Navigating a Rebalanced Hemostatic State in Decompensated Cirrhosis
-
Mar 17, 2026, 17:21Matías J Alet on Acute Ischemic Stroke With Low NIHSS at NeuroQuality